Manager TitleAgeSince
Director of Finance/CFO - 2021-05-12
Chief Tech/Sci/R&D Officer - 2022-06-30
Chief Tech/Sci/R&D Officer - 2015-01-21
Director TitleAgeSince
Director/Board Member - 2024-03-26
Director/Board Member - 2024-03-26
Director/Board Member - 2024-12-03
Date Insider Type Main position Quantity % Market Cap.
20-12-28Sell

Chairman

100,000 0.0358%
20-11-11Free

Director

4,000,000 1.4302%
20-04-14Sell

Chairman

68,707 0.0295%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.04% - - 10.71M
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+1.17%+5.83%+16.39%+468.18% 24.18B
+0.38%+1.33%-14.32%-11.76% 23.75B
-1.47%+4.74%+44.67%-4.13% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-7.47%+9.03%+34.96% - 15.57B
+2.79%+4.91%+29.26%+195.60% 13.96B
Average -0.13%+5.40%+56.00%+150.67% 27.06B
Weighted average by Cap. -0.66%+2.61%+57.82%+139.26%
Logo MEDB CLIN
Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company. The Company specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals with the objective of empowering patients with chronic diseases and mental health conditions and enhancing their lives. Its drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress. It also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. It is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas.
Employees
-